search
Back to results

Safety of VSL#3 in Adult Asthmatics

Primary Purpose

Asthma

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
VSL#3
VSL#3 or placebo
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, Probiotic, VSL#3

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Adults age 18-64 years old.
  2. Doctor diagnosis of mild persistent asthma. Persistent asthma is defined by NAEPP guidelines as asthma symptoms (cough/wheeze/dyspnea/exercise limitation)of greater than 2 times/week daytime or greater than 2 times/month at night over the previous month but less than continual and less than 5 nights/week.
  3. FEV1 greater than 60% predicted for age/gender/race/height based on normative data.
  4. No unscheduled asthma related health visit in the 1 month prior to enrollment
  5. School or work days missed less than or equal to 2 in the previous month for asthma.
  6. Albuterol use less than 8 doses (2 puffs or one neb) in past week.
  7. Ability to speak and understand English.
  8. Telephone access.
  9. Women of childbearing potential must confirm that they will use birth control while in the study and have a negative urine pregnancy screen at baseline.

Exclusion Criteria:

  1. Pregnant women, prisoners.
  2. Chronic illness (other than asthma, allergic rhinitis and eczema) such as renal disease, diabetes, hypertension or terminal disease or abnormal vital signs: T> 100.3F, HR>130 bpm, SBP>155 mmHg, or DBP>100 mmHg, RR>25 bpm, or pox<93% room air.
  3. Unable to perform spirometry, necessary for lung function assessment.
  4. Received probiotic in past 6 months.
  5. Subject or household member has immunosuppression such as HIV, history of organ transplantation, present cancer or chemotherapy, primary immune disease, or is taking an immune modulating drug.
  6. Severe persistent asthmatics who have continual daily or frequent (greater than 5 nights/week) asthma symptoms and/or FEV1 less than 60% predicted .
  7. Diarrhea or constipation (symptoms more than once in the past week)
  8. Unable to feed orally or to consume cornstarch
  9. Lung disease other than asthma (e.g. COPD, cystic fibrosis, lung cancer, bronchiectasis, interstitial lung disease).
  10. Subjects at increased risk of developing infective endocarditis such as those with a history of cardiac surgery, IV drug abuse, recent invasive medical procedures or dental work (recent = last month).
  11. Allergy to Vancomycin or Cefepime. The parameters of intestinal barrier function, intestinal flora, serum inflammatory cytokines, IgE, will have no exclusion ranges as these will be collected over time on product as a way of describing the population characteristics of study participants.

Sites / Locations

  • University of Maryland Baltimore

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

VSL#3

Arm Description

Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria

Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.

Outcomes

Primary Outcome Measures

Safety of VSL#3 in Adults Asthmatics
Change in FEV in adult asthmatics receiving VSL3# as compared to controls receiving placebo.

Secondary Outcome Measures

Full Information

First Posted
February 13, 2009
Last Updated
March 23, 2023
Sponsor
University of Maryland, Baltimore
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00852124
Brief Title
Safety of VSL#3 in Adult Asthmatics
Official Title
Safety of VSL#3 for Adult Asthmatics
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Terminated
Why Stopped
Inadequate recruitment
Study Start Date
February 2007 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore
Collaborators
National Center for Complementary and Integrative Health (NCCIH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
We are proposing to test the safety of the probiotic, VSL#3, in a placebo controlled double blind safety study in 30 asthmatic adults. This adult safety trial was requested by the FDA IND review of a pediatric asthma protocol. Adults with a doctor diagnosis of persistent asthma will take VSL#3 or placebo twice daily for 3 months. Data will be collected, including age, race, height, and weight, present medications, past medical history with emphasis on signs/symptoms of asthma. On visits to the clinic we will evaluate Changes in lung function Intestinal permeability Intestinal bacteria Levels of inflammation in the blood Women will have repeat urine pregnancy testing at each clinic visit
Detailed Description
The monitored parameters that will be assessed at each clinic visit or phone call include: the number of days with asthma related symptoms of cough, wheeze, dyspnea, awakening at night, and exercise limitation. the number of asthma-related missed school/work days the amount of use of asthma rescue medications use of non-inhaled steroids change in medications from baseline visit diarrhea/liquid stools (> 2/day) constipation gas/bloating fever/chills scheduled or unscheduled visits for health care To monitor for increased risk of safety concerns, we will also inquire on follow up visits and phone calls about the following: 1. household member with immunosuppression such as HIV or chemotherapy. On visits to the clinic we will evaluate lung function by spirometry: change in lung function with spirometry. women of childbearing potential will have repeat urine pregnancy testing at each clinic visit. intestinal barrier function intestinal flora serum inflammatory cytokines and IgE

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Probiotic, VSL#3

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
Arm Title
VSL#3
Arm Type
Active Comparator
Arm Description
Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
Intervention Type
Biological
Intervention Name(s)
VSL#3
Intervention Description
VSL#3 2 times daily
Intervention Type
Biological
Intervention Name(s)
VSL#3 or placebo
Intervention Description
1 packet 2 x daily of placebo
Primary Outcome Measure Information:
Title
Safety of VSL#3 in Adults Asthmatics
Description
Change in FEV in adult asthmatics receiving VSL3# as compared to controls receiving placebo.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults age 18-64 years old. Doctor diagnosis of mild persistent asthma. Persistent asthma is defined by NAEPP guidelines as asthma symptoms (cough/wheeze/dyspnea/exercise limitation)of greater than 2 times/week daytime or greater than 2 times/month at night over the previous month but less than continual and less than 5 nights/week. FEV1 greater than 60% predicted for age/gender/race/height based on normative data. No unscheduled asthma related health visit in the 1 month prior to enrollment School or work days missed less than or equal to 2 in the previous month for asthma. Albuterol use less than 8 doses (2 puffs or one neb) in past week. Ability to speak and understand English. Telephone access. Women of childbearing potential must confirm that they will use birth control while in the study and have a negative urine pregnancy screen at baseline. Exclusion Criteria: Pregnant women, prisoners. Chronic illness (other than asthma, allergic rhinitis and eczema) such as renal disease, diabetes, hypertension or terminal disease or abnormal vital signs: T> 100.3F, HR>130 bpm, SBP>155 mmHg, or DBP>100 mmHg, RR>25 bpm, or pox<93% room air. Unable to perform spirometry, necessary for lung function assessment. Received probiotic in past 6 months. Subject or household member has immunosuppression such as HIV, history of organ transplantation, present cancer or chemotherapy, primary immune disease, or is taking an immune modulating drug. Severe persistent asthmatics who have continual daily or frequent (greater than 5 nights/week) asthma symptoms and/or FEV1 less than 60% predicted . Diarrhea or constipation (symptoms more than once in the past week) Unable to feed orally or to consume cornstarch Lung disease other than asthma (e.g. COPD, cystic fibrosis, lung cancer, bronchiectasis, interstitial lung disease). Subjects at increased risk of developing infective endocarditis such as those with a history of cardiac surgery, IV drug abuse, recent invasive medical procedures or dental work (recent = last month). Allergy to Vancomycin or Cefepime. The parameters of intestinal barrier function, intestinal flora, serum inflammatory cytokines, IgE, will have no exclusion ranges as these will be collected over time on product as a way of describing the population characteristics of study participants.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alessio Fasano, M. D.
Organizational Affiliation
MBRC
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Maryland Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
12043385
Citation
Bienenstock J, Wiley RE, Neigh GS, Waserman S, Keith P. Probiotics in the management and prevention of atopy. Clin Rev Allergy Immunol. 2002 Jun;22(3):275-85. doi: 10.1007/s12016-002-0012-z. No abstract available.
Results Reference
background
PubMed Identifier
10950897
Citation
Hijazi N, Abalkhail B, Seaton A. Diet and childhood asthma in a society in transition: a study in urban and rural Saudi Arabia. Thorax. 2000 Sep;55(9):775-9. doi: 10.1136/thorax.55.9.775.
Results Reference
background
PubMed Identifier
12582309
Citation
Kalliomaki M, Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol. 2003 Feb;3(1):15-20. doi: 10.1097/00130832-200302000-00003.
Results Reference
background
PubMed Identifier
10202341
Citation
Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy. 1999 Mar;29(3):342-6. doi: 10.1046/j.1365-2222.1999.00560.x. Erratum In: Clin Exp Allergy 2000 Jul;30(7):1047.
Results Reference
background
PubMed Identifier
14977697
Citation
Hijazi Z, Molla AM, Al-Habashi H, Muawad WM, Molla AM, Sharma PN. Intestinal permeability is increased in bronchial asthma. Arch Dis Child. 2004 Mar;89(3):227-9. doi: 10.1136/adc.2003.027680.
Results Reference
background
PubMed Identifier
18542035
Citation
Isolauri E, Salminen S; Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S91-6. doi: 10.1097/MCG.0b013e3181639a98.
Results Reference
background
PubMed Identifier
17289135
Citation
Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007 Apr;119(4):1019-21. doi: 10.1016/j.jaci.2006.12.608. Epub 2007 Feb 7. No abstract available.
Results Reference
background
PubMed Identifier
16197582
Citation
Laitinen K, Kalliomaki M, Poussa T, Lagstrom H, Isolauri E. Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years. Br J Nutr. 2005 Oct;94(4):565-74. doi: 10.1079/bjn20051503.
Results Reference
background
PubMed Identifier
10651770
Citation
Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, Bohm O, von Kries R. Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy. 2000 Feb;30(2):187-93. doi: 10.1046/j.1365-2222.2000.00801.x.
Results Reference
background
PubMed Identifier
15321991
Citation
Noverr MC, Noggle RM, Toews GB, Huffnagle GB. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun. 2004 Sep;72(9):4996-5003. doi: 10.1128/IAI.72.9.4996-5003.2004.
Results Reference
background
PubMed Identifier
11297958
Citation
Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9. doi: 10.1016/S0140-6736(00)04259-8.
Results Reference
background
PubMed Identifier
11122221
Citation
Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000 Dec;30(12):1804-8. doi: 10.1046/j.1365-2222.2000.00948.x.
Results Reference
background
PubMed Identifier
11157355
Citation
Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001 Feb;73(2 Suppl):444S-450S. doi: 10.1093/ajcn/73.2.444s.
Results Reference
background
PubMed Identifier
15629974
Citation
Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005 Jan;115(1):5-9. doi: 10.1542/peds.2004-1815.
Results Reference
background
PubMed Identifier
15629999
Citation
Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005 Jan;115(1):178-81. doi: 10.1542/peds.2004-2137.
Results Reference
background
PubMed Identifier
15599646
Citation
Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):31-40. doi: 10.1007/s10096-004-1253-y.
Results Reference
background
PubMed Identifier
16126047
Citation
Rinne M, Kalliomaki M, Arvilommi H, Salminen S, Isolauri E. Effect of probiotics and breastfeeding on the bifidobacterium and lactobacillus/enterococcus microbiota and humoral immune responses. J Pediatr. 2005 Aug;147(2):186-91. doi: 10.1016/j.jpeds.2005.03.053.
Results Reference
background

Learn more about this trial

Safety of VSL#3 in Adult Asthmatics

We'll reach out to this number within 24 hrs